Altogether, these results support evidence that IL-33 acts asa potent adjuvant capable ofinducing and modulating potent Ag-specific cell-mediated immunity in a variety of pathogens.
Together, these results indicate that the increase in the frequency and
phenotype of the IL-33-adjuvanted vaccine-induced Ag-specific P14 CD8
T cells after a prime
and boost vaccination may be a prediction of the protective correlates ofimmunity behind the
therapeutic efficacy of immunoadjuvant IL-33 against the established TC-1 tumors (Fig. 6B). We
are currently investigating the ability of IL-33 to generate central memory immunity, since
central memory T cells are important subsets of memory CD8
T cells that also mediate optimal
protective immunity against pathogens (47,48). Overall, understanding the mechanism of action
by which IL-33 influences the expansion and development of heterogeneous CD8
populations in vaccines is an important area for further investigation.
see... THIS is why nobody invests in this stock... because of this #$%$... no one is going to read that #$%$... and you know it. This company will remain unknown until Merck takes it away from investors. It's your own damn fault, you pompous assed cretins.